/GLABF
GLABF Stock - Gemina Laboratories Ltd.
Healthcare|BiotechnologyOTC
$0.09+0.00%
+$0.00 (+0.00%) • Dec 19
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.10
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for GLABF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.09 – $0.09
TARGET (TP)$0.10
STOP LOSS$0.08
RISK/REWARD1:1.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.03
52W High$0.92
52W Low$0.09
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-113,239 | $-93,368 | $-50,282 | $-43,834 | $-12,090 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-3,911,951 | $-5,085,883 | $-5,980,126 | $-4,734,374 | $-645,600 |
| Net Income | $-4,073,658 | $-5,216,789 | $-5,979,027 | $-4,734,913 | $-834,153 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.06 | $-0.07 | $-0.10 | $-0.10 | $-0.02 |
Company Overview
Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company develops novel surface functionalization chemistries for the detection of pathogens and biomarkers. It is developing POC Antigen COVID test, a point-of-care lateral flow assay test strip to test whether or not a person is currently infected with COVID-19. The company is headquartered in Vancouver, Canada.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
GLABFBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.00
Q3 2025
EPS Surprise History
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q4 24
No data
Q2 25
No data
Q2 25
No data
Q3 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 26, 2026 | — | — | — | — |
Q4 2025 | Dec 29, 2025 | — | — | — | — |
Q3 2025 | Sep 25, 2025 | — | $-0.00 | — | — |
Q2 2025 | Jun 26, 2025 | — | $-0.01 | — | — |
Q2 2025 | May 28, 2025 | — | $-0.01 | — | — |
Q4 2024 | Dec 30, 2024 | — | $-0.01 | — | — |
Q4 2024 | Dec 25, 2024 | — | $-0.01 | — | — |
Q3 2024 | Sep 27, 2024 | — | $-0.01 | — | — |
Q2 2024 | Jun 28, 2024 | — | $-0.01 | — | — |
Q1 2024 | Jan 30, 2024 | — | $-0.01 | — | — |
Q4 2023 | Oct 31, 2023 | — | $-0.01 | — | — |
Q3 2023 | Jul 31, 2023 | — | $-0.02 | — | — |
Q2 2023 | Apr 30, 2023 | — | $-0.02 | — | — |
Q1 2023 | Jan 31, 2023 | — | $-0.02 | — | — |
Q4 2022 | Oct 31, 2022 | — | $-0.01 | — | — |
Q3 2022 | Jul 31, 2022 | — | $-0.03 | — | — |
Q2 2022 | Apr 30, 2022 | — | $-0.01 | — | — |
Q1 2022 | Jan 31, 2022 | — | $-0.02 | — | — |
Q4 2021 | Oct 31, 2021 | — | $-0.02 | — | — |
Q3 2021 | Jul 31, 2021 | — | $-0.01 | — | — |
Latest News
Loading news...
Frequently Asked Questions about GLABF
What is GLABF's current stock price?
Gemina Laboratories Ltd. (GLABF) is currently trading at $0.09 per share. The stock has moved +0.00% today.
What is the analyst price target for GLABF?
No analyst price targets are currently available for this stock.
What sector is Gemina Laboratories Ltd. in?
Gemina Laboratories Ltd. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is GLABF's market cap?
Gemina Laboratories Ltd. has a market capitalization of $0.01 billion, making it a small-cap company.
Does GLABF pay dividends?
No, Gemina Laboratories Ltd. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACMSY
AccuStem Sciences Limited
$0.13
0CLCS
Cell Source, Inc.
$0.50
Mkt Cap: $0.0B
HMTXF
Hemostemix Inc.
$0.06
Mkt Cap: $0.0B
PPCB
Propanc Biopharma, Inc.
$0.71
Mkt Cap: $0.0B
PRVCF
PreveCeutical Medical Inc.
$0.02
Mkt Cap: $0.0B
QPTFF
Quest PharmaTech Inc.
$0.01
Mkt Cap: $0.0B
SRBCF
Sirona Biochem Corp.
$0.01
Mkt Cap: $0.0B
SYGGF
Synairgen plc
$0.00
Mkt Cap: $0.0B
TELIF
Telescope Innovations Corp.
$0.25
Mkt Cap: $0.0B
ZHCLF
Zenith Capital Corp.
$0.00
Mkt Cap: $0.0B
Explore stocks similar to GLABF for comparison